Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Amino acids for renal protection: time to implement in clinical practice.

Korean journal of anesthesiology·2026
Same author

Sex-related mortality differences in septic shock: A propensity score-matched study.

Journal of critical care·2026
Same author

Association of duration of amino acids infusion and renal protection: a secondary analysis of the PROTECTION trial.

British journal of anaesthesia·2026
Same author

Neurocognitive outcomes: methodological clarifications.

Anaesthesia·2026
Same author

Acute normovolaemic haemodilution after cardiac surgery: a meta-analysis of randomised controlled trials.

British journal of anaesthesia·2026
Same author

Diabetes does not modify the renal-protective effect of intravenous amino acids infusion after cardiac surgery.

Journal of endocrinological investigation·2026

相关实验视频

Updated: Jul 7, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

芬诺多巴姆在接受心脏手术的高风险患者中的保护作用:一个前性,双盲,随机的临床试验.

Tiziana Bove1, Giovanni Landoni, Maria Grazia Calabrò

  • 1Department of Cardiovascular Anesthesia, Vita-Salute University of Milan, IRCCS San Raffaele Hospital, Milan, Italy.

Circulation
|June 22, 2005
PubMed
概括

芬诺多巴姆在预防高风险心脏手术患者急性功能衰竭方面没有比多巴胺显著的益处. 这两种治疗都导致类似的功能障碍和其他不良结果.

更多相关视频

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

相关实验视频

Last Updated: Jul 7, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

科学领域:

  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 急性衰竭 (ARF) 是心脏手术后的一种严重并发症,与增加的发病率和死亡率有关.
  • 接受心脏手术的患者有患上外科手术期间功能障碍的风险.

研究的目的:

  • 评估选择性多巴胺-1受体激动剂芬诺多巴姆在预防高风险心脏手术患者的外科手术期间功能障碍方面的疗效.
  • 为了在这个患者群体中比较诺多巴与多巴胺对脏保护的作用.

主要方法:

  • 一项前性,随机,双盲试验,涉及80名高风险心脏手术患者 (心脏手术计划得分>10).
  • 患者在麻醉诱导后的24小时内接受了芬诺多巴 (0.05微克/千克/分钟) 或多巴胺 (2.5微克/千克/分钟).
  • 主要终点是从外科手术后的基线增加25%的肌素.

主要成果:

  • 芬诺多巴姆 (42.5%) 和多巴胺 (40%) 组之间急性功能衰竭的发生率没有显著差异 (P=0.9).
  • 术后血清肌素峰值,ICU和住院,以及死亡率在两组之间是可比的.
  • 研究队列均,表明可靠的比较.

结论:

  • 芬诺多巴姆在降低心脏手术的高风险患者急性功能衰竭的发生率方面没有证明它比多巴胺具有临床优势.
  • 尽管现有关于芬诺多对脏的保护作用的报告,但这项研究发现,与多巴胺相比,临床结果没有差异.